The team's approach begins with neural progenitor cells derived from human stem cells. By exposing these cells to conditions mimicking the oxygen-depleted environment of an injured brain—a process called hypoxia conditioning—the researchers coaxed them to produce EVs loaded with potent wound-healing factors. These include miRNA-9, which promotes the birth of new neurons, and VEGF (vascular endothelial growth factor), which stimulates blood vessel formation and helps restore the protective blood-brain barrier.
The researcher’s innovative approach utilizes BIOGEL to effectively deliver the EVs to the injury site. BIOGEL encapsulates the EVs and has mechanical properties that closely match those of healthy brain tissue, providing structural support while allowing new cells to infiltrate and grow. Importantly, BIOGEL releases its therapeutic cargo gradually over several days, ensuring sustained delivery exactly where it's needed most—at the injury site.
They then validated the efficacy of their platform in preclinical studies using a rat model of TBI. Animals treated with this combined therapy showed dramatic improvements across multiple measures: significantly reduced brain tissue damage, enhanced growth of new neurons in the hippocampus (a region critical for memory and learning), restored protective myelin sheaths around nerve fibers, and reduced harmful inflammation. The cellular and structural advancements led to significant functional recovery; specifically, animals treated outperformed the control group in neurological tests and motor function evaluations.
What sets this therapeutic strategy apart is its multi-pronged approach. Rather than targeting just one aspect of brain injury, the BIOGEL-EV platform addresses several critical challenges simultaneously: it modulates harmful inflammation, provides structural support for tissue regeneration, delivers pro-regenerative factors, promotes new blood vessel formation, and creates a hospitable environment for neural repair. The treatment effectively "reprograms" the injury site from a hostile, inflammatory environment into one that supports healing and recovery.
Perhaps most importantly, this approach offers a potential path forward for clinical translation. Unlike strategies requiring invasive surgery, BIOGEL can be administered through minimally invasive injection. Using stem cell-derived EVs rather than whole cells sidesteps many of the safety concerns and technical challenges associated with cell transplantation. At the same time, the biomaterial components are based on gelatin—a well-established, biocompatible material with a long history of medical use.
Looking ahead, this research opens exciting possibilities not only for TBI treatment but also potentially for other neurological conditions involving inflammation and tissue damage. The modular nature of the platform—combining a customizable biomaterial scaffold with engineered therapeutic vesicles—suggests it could be adapted for treating stroke, spinal cord injury, and other central nervous system disorders. By simultaneously addressing inflammation, vascular dysfunction, and neural circuit repair, this innovative approach represents a significant step forward in our ability to help the brain heal itself.
Publication: J.B. Stein, S. Zhang, E.J. Roh, J. Luo, M. Chen, H. Jang, L.L. Goldston, B. Conklin, I. Han, K.-B. Lee, Advanced Biomaterial Delivery of Hypoxia-Conditioned Extracellular Vesicles (EVs) as a Therapeutic Platform for Traumatic Brain Injury. Adv. Sci. 2025, e202504147. https://doi.org/10.1002/advs.202504147